Telix Pharmaceuticals Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was AUD 502.55 million compared to AUD 160.1 million a year ago. Net income was AUD 5.21 million compared to net loss of AUD 104.08 million a year ago.

Basic earnings per share from continuing operations was AUD 0.0163 compared to basic loss per share from continuing operations of AUD 0.335 a year ago. Diluted earnings per share from continuing operations was AUD 0.0161 compared to diluted loss per share from continuing operations of AUD 0.335 a year ago.